Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTSW), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) is an Israeli clinical-stage oncology therapeutics company developing Alpha DaRT®, a radium-224–based intratumoral alpha-radiation therapy for solid tumors. The news flow around Alpha Tau centers on clinical trial progress, regulatory interactions, and operational milestones related to this technology.
Company press releases describe ongoing and planned studies of Alpha DaRT in several high-need cancer indications, including recurrent cutaneous squamous cell carcinoma, pancreatic ductal adenocarcinoma, recurrent glioblastoma multiforme, recurrent squamous cell carcinoma of the oral cavity, and locally recurrent prostate cancer. News items highlight first-in-human treatments, such as the first patient treated in a U.S. multi-center pancreatic cancer trial and the first patient treated with Alpha DaRT in the brain for recurrent glioblastoma.
Regulatory and development updates are another recurring theme. Alpha Tau reports Breakthrough Device Designation from the U.S. Food and Drug Administration for multiple indications, participation in the FDA’s Total Product Life Cycle Advisory Program for recurrent GBM, and submission of the first module of a pre-market approval application for Alpha DaRT in recurrent cutaneous squamous cell carcinoma using a modular framework. The company also discloses FDA approval of an Investigational Device Exemption for a pilot study in locally recurrent prostate cancer.
Operational and corporate news includes securing a radioactive material license for a commercial-scale Alpha DaRT manufacturing facility in New Hampshire, interim financial results, and participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Sidoti, and Jefferies. Investors and observers following DRTS and DRTSW can use this news page to review Alpha Tau’s reported clinical milestones, regulatory steps, manufacturing preparation, and capital markets activities as they relate to the Alpha DaRT platform.
Alpha Tau (Nasdaq: DRTS) received a radioactive material license from the State of New Hampshire Radiological Health Section for the first phase of its commercial-scale manufacturing facility in Hudson, New Hampshire.
The standalone building exceeds 14,000 rentable square feet and the first-phase nameplate capacity is approximately 400,000 Alpha DaRT sources for local use. The license allows the company to introduce thorium generators, equip the plant, and proceed with verification and validation steps aimed at producing Alpha DaRT treatments during 2026. Alpha DaRT is under evaluation in multiple clinical trials across several tumor types, including skin, head & neck, pancreas, lung, prostate, and brain.
Alpha Tau Medical (NASDAQ: DRTS) has announced the successful treatment of its first patient in the U.S. multi-center pancreatic cancer pilot study called IMPACT (Intratumoral Pancreatic Alpha Combination Trial). The study evaluates the company's innovative Alpha DaRT® therapy combined with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.
The treatment was performed at University Cancer Centers in Houston, utilizing a minimally invasive approach under endoscopic ultrasound guidance. The trial addresses a critical medical need, as up to 87% of pancreatic cancer patients are deemed inoperable at diagnosis, with pancreatic cancer being the third leading cause of cancer-related death in the U.S., affecting approximately 66,000 new cases annually.
Alpha Tau Medical (NASDAQ: DRTS), developer of the innovative Alpha DaRT® alpha-radiation cancer therapy, announced CFO Raphi Levy's participation in five investor conferences this September 2025. The Alpha DaRT platform represents a novel approach to solid tumor treatment using localized alpha particle radiotherapy, designed to destroy tumors while preserving healthy tissue.
The conferences include the Citi Biopharma Back to School Summit, H.C. Wainwright Global Investment Conference, Oppenheimer's Targeted Radiopharmaceutical Therapies Summit, RTH & Co Radiopharma Conference, and Lytham Partners Fall Conference. The company expects key milestones and pivotal data from multiple clinical trials in 2025-2026.
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, reported Q2 2025 financial results and corporate updates. The company received FDA approval for an IDE to conduct a U.S. pilot study for recurrent glioblastoma multiforme (GBM) treatment. Alpha Tau secured $36.9 million through strategic equity offering from Oramed and maintains a strong cash position of $83.3 million.
The company is advancing multiple U.S. clinical trials, including studies in pancreatic cancer and GBM, with patient treatments expected to begin in 2025. Their ReSTART pivotal skin cancer trial is nearing completion. The company's first phase of their Hudson, NH commercial facility is expected to be operational by early 2026. For H1 2025, Alpha Tau reported a net loss of $18.8 million ($0.25 per share), compared to $15.4 million ($0.22 per share) in H1 2024.
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CFO Raphi Levy will deliver a presentation on June 5, 2025, from 1:25 to 1:55 PM ET in New York. Additionally, Mr. Levy will be available for one-on-one meetings with investors during the conference, which can be scheduled through Jefferies representatives.
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, has appointed Nadav Kidron to its Board of Directors. Kidron, who currently serves as President, CEO, and Chairman of Oramed Pharmaceuticals, joins following a strategic investment between Alpha Tau and an Oramed affiliate. With extensive experience leading a public company in therapeutic innovation, Kidron brings valuable expertise as Alpha Tau progresses toward commercialization. His background includes leadership roles at MDG Real Estate Global, Israel Advanced Technology Industries Organization, and previous directorship at Entera Bio. Kidron holds an LL.B. and International MBA from Bar Ilan University.
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, announced its CFO Raphi Levy's participation in two upcoming investor conferences in May 2025. Levy will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, from 3:30-4:00 PM ET in New York. Additionally, he will attend the Lytham Partners Spring 2025 Investor Conference virtually on May 29, 2025, for one-on-one meetings. Investors can schedule meetings with Mr. Levy at both conferences through their respective H.C. Wainwright and Lytham Partners representatives.
Alpha Tau Medical (NASDAQ: DRTS) has successfully closed a $36.9 million registered direct offering with Oramed Pharmaceuticals. The deal involves the sale of 14,110,121 ordinary shares at $2.612 per share to an Oramed affiliate.
The company plans to use the proceeds for general corporate purposes, including R&D for product candidates, manufacturing expansion, and potential commercialization efforts. Additionally, an Oramed affiliate will provide strategic services in investor and public relations over three years in exchange for payments and warrants for additional Alpha Tau shares.
The investment aligns with Alpha Tau's current growth phase, marked by four active U.S. trial approvals, expansion into multiple internal organ applications, manufacturing scale-up, and ongoing commercial preparations for their Alpha DaRT® alpha-radiation cancer therapy.
Alpha Tau Medical (NASDAQ: DRTS) has received FDA approval for an Investigational Device Exemption (IDE) to begin a pilot study treating recurrent glioblastoma (GBM) patients with their Alpha DaRT® technology. The trial will enroll up to 10 U.S. patients with recurrent GBM who are not candidates for surgery and have previously undergone central nervous system radiation.
The study's primary goal is to assess the feasibility and safety of the treatment, building on promising pre-clinical results. This approval follows the FDA's earlier Breakthrough Device Designation and acceptance into the FDA's Total Product Life Cycle Advisory Program, aimed at accelerating the Alpha DaRT treatment's path to market.
Glioblastoma is described as one of the most complex and treatment-resistant cancers, with an average survival rate of only 8 months, according to the National Brain Tumor Society.